Skip to main content
World Health Organization Logo

World Health Organization Delving Into the Status of CBD in November

Following a public comment period initiated by the United States Food & Drug Administration on behalf of the United Nations and the World Health Organization on the potential medical benefits of Cannabidiol, or CBD, and sixteen other drug substances, the WHO plans to meet in Geneva this November "to review the substances and begin work on potential recommendations to the United Nations Secretary-General." This assembly will be the 39th Meeting of the WHO's Expert Committee on Drug Dependence.

Although this is the beginning of a long process, after the November 6-10th meeting CBD could be in a very different place on the world stage. And considering the amount of feedback the FDA and WHO have received so far, they certainly have a lot of information and opinions to work with. According to The Cannabist, which is publishing an extended series of articles on the legal and regulatory landscape of CBD:

The United States Hemp Roundtable — the entity behind the website, formed to drum up support and written comments — joined several thousand public comments submitted to the FDA. The organization of businesses that make hemp-derived, CBD-rich products claimed that the cannabis compound should not be shepherded solely to the realm of pharmaceuticals.

“The structure and nature of the FDA forces definition into food, drug and supplements and the grey area of all the other products not classified,” Brian Furnish, the U.S. Hemp Roundtable’s president, wrote in a letter submitted as part of the public comment process. “CBD produced from hemp is not a controlled substance, so it is clearly not a drug. The FDA, with antiquated rules that only benefit pharmaceutical companies, says that CBD is not a supplement.

“That means CBD derived from hemp is food.”

As the public comment period was starting to draw to a close on Wednesday, more than 6,400 comments had been submitted — the vast majority of which were about CBD, according to The Cannabist’s review. More than 1,000 comments were pre-written responses suggested by, The Cannabist found.

Whether those comments are heard or acted upon by international experts remains to be seen.

Photo via Wikimedia Commons.